BUDGET IMPACT ANALYSIS OF SECUKINUMAB IN MODERATE TO SEVERE PLAQUE PSORIARIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS IN FRANCE

Author(s)

Duteil E, Rachdi L, Cariou C, Benjamin K, Leiba G, Duco J
Novartis Pharma, Rueil-Malmaison, France

Presentation Documents

OBJECTIVES:  To assess the budget impact of the introduction of secukinumab, the first anti-IL 17a in the biologics arsenal for patients with moderate to severe plaque psoriasis (PP), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) in France over the next years. METHODS: A budgetary impact model was developed to estimate healthcare costs of the addition of secukinumab in the biologics arsenal to treat PP, AS and PsA, during a 6-year period under a French collective perspective. Nine biologics of which 3 biosimilars were implemented in the model: etanercept (originator and biosimilar), adalimumab (originator and biosimilar), infliximab (originator and biosimilar), certolizumab, golimumab and ustekinumab. Health care consumption was valued using French databases. As the model used differential costs, only treatment costs were included. Infliximab was the only biologic treatment with a hospital-based administration. Due to this specificity, the cost of the administration (GHM 28Z17Z) was added to the cost of infliximab. Costs were expressed in euros (€, 2016) and no discount rate was applied.  RESULTS:

The number of patients estimated to be treated by secukinumab over the next 6 years was 24,979; in PP, AS and PsA respectively. The incremental cost of the introduction of secukinumab added million € (M€) the first year and saved M€, 14.9 M€, m€, 21.3 M€ and 23.0 M€ in the second, third, fourth, fifth and sixth year respectively. Regarding the 6-year period, secukinumab utilization lead to save M€ in the collective perspective. CONCLUSIONS:

The introduction of secukinumab in the treatment of PP, AS and PsA would imply a budget impact decrease of M€ for the healthcare system and society in the French setting.

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PHP106

Topic

Economic Evaluation

Topic Subcategory

Budget Impact Analysis

Disease

Sensory System Disorders, Systemic Disorders/Conditions

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×